Gedeon/Actavis's new cariprazine data enough in schizophrenia?
This article was originally published in Scrip
Gedeon Richter and Actavis's novel antipsychotic cariprazine has shown positive top-line Phase III results in preventing relapse in patients with schizophrenia, but analysts doubt that they will be enough to propel decent sales of the product in the presence of generic competition.
You may also be interested in...
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.